Urokit granules 3g No. 20

Composition
3 g of granules for oral solution contain 3 g of potassium citrate as the active ingredient. Excipients: aspartame 0.025 g, tricalcium phosphate 0.015 g, silicon dioxide 0.004 g.

Pharmacotherapeutic group
Agent that inhibits the formation of urinary stones and eliminates them in the urine. Code G04BC.

Pharmacological properties
Potassium citrate reduces the saturation of urine with calcium salts by binding calcium and reducing the concentration of calcium ions. Due to this alkalizing effect, it also increases the dissociation of uric acid, reducing the amount of poorly soluble undissociated acid, and reduces the tendency to form urate stones. Urocit regulates urine pH and maintains a long-term alkaline pH shift to pH values of 6.2-7.5, at which uric acid salts remain in solution and do not form stones.

Pharmacokinetics

Under normal conditions, most of the potassium citrate taken orally is absorbed. Almost all of the absorbed citrate is oxidized under normal conditions, leaving potassium ions free, thus forming an alkaline load. This alkaline load raises the pH and increases the amount of citrate in the urine. This indicates that a small amount of absorbed citrate is not oxidized and is found in the urine. About 75% of the citrate filtered by the kidneys is reabsorbed, while 25% is eliminated in the urine. In cases of hypokalemia, potassium ions themselves increase urinary citrate excretion, attempting to correct intracellular acidosis.

Indications. Prevention and treatment of uric acid stones (single-phase calcium oxalate, urate, and multi-phase (mixed), calcium oxalate, and calcium phosphate stones).
Nephrurolithiasis and cystinuria (adjunctive therapy). Alkalization of urine in cutaneous porphyria, uricosuria, and treatment with cytostatics.

Method of administration and dosage

To prepare 1 single dose, dissolve 1 sachet in 200 ml of water. For calcium stones accompanied by hypocitraturia: For moderate hypocitraturia, 1 single dose twice daily. For severe hypocitraturia (associated with renal tubular acidosis), 2 single doses twice daily. For calcium stones accompanied by hyperuricosuria, 1-2 single doses daily, divided into two doses. For calcium stones without hyperuricosuria, 1/3 sachet twice daily.

Side effects

Moderate gastrointestinal disturbances, such as abdominal discomfort, nausea, vomiting, and diarrhea, may occur. These symptoms may be reduced when the medication is taken with food.

Contraindications

Contraindications
Renal failure. Urinary tract infections. Urinary tract obstruction. Hypernatremia. Adrenocortical insufficiency. Hypokalemia. Hypochlorhydria. Metabolic or respiratory alkalosis. Active peptic ulcer. Intestinal obstruction. Patients taking anticholinergic therapy. Cardiac disease that may be worsened by potassium supplementation.

Warning.
Patients with altered potassium excretion, such as renal failure, are at risk of life-threatening hypernatremia.

Recommendations.
Plasma electrolytes (sodium, potassium, and chloride), creatinine, and hemogram are recommended to be monitored every 4 months. Patients taking Urokit are advised to follow a low-salt diet and increase fluid intake.

Overdose

Long-term use of the drug in patients with impaired potassium excretion may lead to hypernatremia. This, in turn, may cause muscle paralysis and cardiovascular collapse.

Release conditions

By doctor's prescription.

Storage conditions

Store out of reach of children, in a dry, dark place, at a temperature not exceeding 30°C.

Release form

In a box with 20, 60 single doses of the drug.

Expiration date

36 months.

Order